Spray drying has been used extensively in the pharmaceutical industry for a variety of particle engineering applications, including for the manufacture of bioavailability-enhancing formulations such as spray dried dispersions (SDDs) of drugs and polymers, more generally termed amorphous solid dispersions (ASDs). The process is continuous and readily scalable to accommodate the needs of a program, from early feasibility assessments through large-scale commercial launch. Spray dried powders can be readily converted to solid dosage forms for oral dosing or dosed as dry powders with a specified device for inhaled applications.
In a recent webinar, “Pharmaceutical Spray Drying: Sustainable Commercial Best Practices to Continuous Project-Focused Innovation,” experts from Lonza discussed the process that Lonza uses to develop a spray dried powder formulation and scale that formulation from early feasibility studies to commercial manufacturing. Following the webinar, presenters Travis Harrer, Manager, Process Engineering, and Jason Bertola, Head of Commercial Development North America, answered questions regarding Lonza’s processes and capabilities.